Scisparc Ltd
SPRC0.684USD
+0.072+11.75%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
365.67KMarket Cap
LossP/E TTM
More Details of Scisparc Ltd Company
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Scisparc Ltd Info
Ticker SymbolSPRC
Company nameScisparc Ltd
IPO dateDec 22, 2021
CEOWeiss (Amitay)
Number of employees2
Security typeOrdinary Share
Fiscal year-endDec 22
Address20 Raul Wallenberg Street, Tower A
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6971916
Phone97236103100
Websitehttps://scisparc.com/
Ticker SymbolSPRC
IPO dateDec 22, 2021
CEOWeiss (Amitay)
Company Executives of Scisparc Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+9.00%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Oz Adler, CPA
Mr. Oz Adler, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Moshe Revach
Mr. Moshe Revach
Director
Director
--
--
Mr. Lior Vider
Mr. Lior Vider
Independent Director
Independent Director
--
--
Ms. Liat Sidi
Ms. Liat Sidi
Director
Director
--
--
Mr. Amnon Shay
Mr. Amnon Shay
Independent Director
Independent Director
--
--
Mr. Alon Dayan
Mr. Alon Dayan
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+9.00%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Oz Adler, CPA
Mr. Oz Adler, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Moshe Revach
Mr. Moshe Revach
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
L.I.A. Pure Capital Ltd
10.01%
Ronen (Fatal)
6.60%
Eli (Zamir)
6.60%
Daniel (Nissim)
6.60%
UBS Financial Services, Inc.
0.58%
Other
69.60%
Shareholders
Shareholders
Proportion
L.I.A. Pure Capital Ltd
10.01%
Ronen (Fatal)
6.60%
Eli (Zamir)
6.60%
Daniel (Nissim)
6.60%
UBS Financial Services, Inc.
0.58%
Other
69.60%
Shareholder Types
Shareholders
Proportion
Individual Investor
19.81%
Corporation
10.01%
Investment Advisor
0.58%
Research Firm
0.03%
Bank and Trust
0.01%
Other
69.56%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
14
27.07K
0.62%
+11.94K
2025Q3
15
9.03K
0.56%
+2.09K
2025Q2
20
5.89K
1.10%
-4.32K
2025Q1
22
123.94K
1.13%
-90.52K
2024Q4
22
186.52K
1.22%
-6.68K
2024Q3
20
179.36K
1.73%
+90.02K
2024Q2
22
138.03K
12.19%
+104.31K
2024Q1
20
67.89K
2.29%
+37.60K
2023Q4
19
11.96K
4.65%
-10.95K
2023Q3
23
5.71K
4.48%
-17.08K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ronen (Fatal)
287.27K
8.73%
+287.27K
--
Nov 28, 2025
Eli (Zamir)
287.27K
8.73%
+287.27K
--
Nov 28, 2025
Daniel (Nissim)
287.27K
8.73%
+287.27K
--
Nov 28, 2025
UBS Financial Services, Inc.
8.00
0%
-3.30K
-99.76%
Sep 30, 2025
BofA Global Research (US)
1.37K
0.04%
+1.36K
+68200.00%
Sep 30, 2025
UBS Switzerland AG
5.40K
0.16%
+5.40K
--
Sep 30, 2025
Shrem (Itschak)
16.00
0%
+9.00
+128.57%
Apr 23, 2025
SBI Securities Co., Ltd.
12.00
0%
-6.00
-33.33%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
--
0%
-1.00
-100.00%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 21, 2025
Merger
21→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Date
Ex-dividend Date
Type
Ratio
May 21, 2025
Merger
21→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
